J&J's RYBREVANT Combo Shows Promise in Head and Neck Cancer, Challenging Standard of Care

Event summary

  • Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combined with pembrolizumab demonstrated a 56% overall response rate (ORR) in a Phase 1b/2 trial (OrigAMI-4) for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
  • The ORR of 56% significantly surpasses the 18% response rate typically achieved with PD-1 monotherapy and modest improvements seen with chemotherapy.
  • The combination therapy resulted in a 10% complete response rate and a clinical benefit rate of 74%, with a median progression-free survival of 7.7 months.
  • An ongoing Phase 3 trial (OrigAMI-5) is evaluating RYBREVANT FASPRO™ with carboplatin and pembrolizumab as a first-line treatment.

The big picture

The results highlight a critical unmet need in head and neck cancer treatment, where current therapies offer limited benefit. J&J’s RYBREVANT combination represents a potential paradigm shift by targeting multiple drivers of tumor growth and resistance, mirroring the success seen in EGFR-mutated lung cancer. The OrigAMI-5 trial will be pivotal in determining whether this approach can be broadly adopted and whether J&J can establish a significant market position in this challenging therapeutic area.

What we're watching

Clinical Validation
The success of OrigAMI-5 will be crucial in establishing RYBREVANT FASPRO™ as a new standard of care, and its results will likely influence adoption rates and pricing strategies.
Competitive Landscape
Other companies are likely to accelerate development of competing therapies targeting EGFR and MET in head and neck cancer, potentially eroding J&J’s market share if OrigAMI-5 fails to confirm the initial findings.
Regulatory Pathway
The FDA’s acceptance of subcutaneous formulations, as demonstrated by the approval of RYBREVANT FASPRO™, could encourage similar development pathways for other biologics, impacting manufacturing costs and patient access.

Related topics

Product Launch Pharmaceuticals Regulatory Approval Drug Development Biotechnology